6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Novel Psychoactive Substances and Emerging Drug Trends
Synthetic compounds that mimic traditional drugs but skirt legal frameworks are complicating addiction landscapes. The proliferation of novel psychoactive substances and emerging drug trends poses significant risks due to unpredictable potency and side effects. These substances often evade detection by standard drug screens, challenging clinicians during diagnosis and treatment. From synthetic cannabinoids to designer stimulants, their impact can be severe, leading to hospitalizations, psychosis, or fatal overdoses. Monitoring systems and toxicological advancements are now essential in keeping pace with new variants. Public awareness campaigns, rapid policy adaptation, and global data sharing are crucial to curbing the spread and harm of these unpredictable substances.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States